CAAS Capital Management’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,600
Closed -$186K 722
2023
Q1
$186K Buy
+1,600
New +$179K 0.01% 568
2022
Q4
Sell
-65,097
Closed -$7.15M 830
2022
Q3
$5.24M Sell
65,097
-4,483
-6% -$380K 0.25% 118
2022
Q2
$5.19M Buy
+69,580
New +$6.35M 0.26% 97
2021
Q3
Sell
-22,284
Closed -$2.81M 999
2021
Q2
$2.38M Sell
22,284
-42,472
-66% -$4.08M 0.04% 365
2021
Q1
$5.82M Buy
64,756
+28,756
+80% +$2.7M 0.06% 326
2020
Q4
$3.33M Buy
+36,000
New +$3.21M 0.03% 391

Other funds holding DXCM

CAAS Capital Management's DXCM Position: Q2 2023 in Review

CAAS Capital Management sold out of DexCom (DXCM) in Q2 2023, closing a stake of 1,600 shares — an estimated $186K sold.

CAAS Capital Management first reported a position in DXCM in Q4 2020 and held it in 6 quarters. The position peaked at $5.82M in Q1 2021. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

  • CAAS Capital Management reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
  • CAAS Capital Management sold 1,600 DexCom shares in Q2 2023, an estimated $186K.
  • CAAS Capital Management first reported a position in DexCom in Q4 2020 and held it in 6 quarters.
  • CAAS Capital Management's DexCom position peaked at $5.82M in Q1 2021.
  • 954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on CAAS Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.